公开(公告)号：US10781265B2

公开(公告)日：2020-09-22

申请号：US15988875

申请日：2018-05-24

Applicant: Development Center for Biotechnology

Inventor： Chia-Cheng Wu ,  Szu-Liang Lai ,  Yu-Jung Chen ,  Chih-Yung Hu ,  Tzu-Yin Lin

IPC: C07K16/34

Abstract: A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX′SGNRRYZLV (SEQ ID NO:7, wherein X′ is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

公开(公告)号：US20200048365A1

公开(公告)日：2020-02-13

申请号：US15988875

申请日：2018-05-24

Applicant: Development Center for Biotechnology

Inventor： Chia-Cheng Wu ,  Szu-Liang Lai ,  Yu-Jung Chen ,  Chih-Yung Hu ,  Tzu-Yin Lin

IPC: C07K16/34

Abstract: A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX′SGNRRYZLV (SEQ ID NO:7, wherein X′ is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

公开(公告)号：US20160068595A1

公开(公告)日：2016-03-10

申请号：US14785139

申请日：2014-04-18

Applicant: Development Center for Biotechnology ,  DCB-USA LLC

Inventor： Chia-Cheng Wu ,  Chao-Yang Huang ,  Yu-Ying Lin ,  Yu-Jung Chen ,  Jiann-Shiun Lai

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: A humanized antibody, or a scFv, Fab, or F(ab′)2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions; and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.

Abstract translation: 人源化抗体或其scFv，Fab或F（ab'）2包括：重链可变区或其同源变体，其中重链可变区包括：重链框架区，CDRH1具有 SEQ ID NO：19的序列，具有SEQ ID NO：20的序列的CDRH2和具有SEQ ID NO：21的序列的CDRH3，其中所述重链可变区和所述同源变体具有至少90％的序列同一性 在重链框架地区; 和轻链可变区或其同源变体，其包括：轻链框架区，具有SEQ ID NO：22的序列的CDRL1，具有SEQ ID NO：23的序列的CDRL2和具有SEQ ID NO：23的CDRL3，其具有 SEQ ID NO：24的序列，其中轻链可变区和同源变体在轻链框架区中共享至少90％的序列同一性。